OUTCOME AND FOLLOW UP
After 10 days of treatment, the patient’s breast enlargement reduced, but moderate fatigue was experienced. He mentioned taking more frequent naps, having low energy, and lacking motivation for the gym. Examination showed mild tenderness in the peri-areolar area and reduced breast tissue. The patient was advised to continue anastrozole and injectable ARVs. However, due to weight gain concerns, he expressed interest in switching to ARV tablets. After reassurance, he was scheduled to switch next month. At week 4 follow-up, the patient tolerated anastrozole well despite fatigue. He switched to TDF/FTC/doravirine tablets at week 6, reporting complete resolution of breast enlargement and tenderness.